Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 15 January, 2020

DBV Technologies S.A.

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF REGULATED INFORMATION
Montrouge, France, January 15, 2020

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.

Under the liquidity contract between DBV Technologies and ODDO BHF, the following assets appeared on the liquidity account as of December 31st, 2019:

  • 9,000 DBV Technologies shares
  • € 1,051,48.5.14

When the agreement was first put in place, the following assets appeared on the liquidity account:

  • 41,159 DBV Technologies shares;
  • € 432,367.25

Over the period from 01/07/2019 to 31/12/2019 were executed:

  • 1,367 purchase transactions
  • 1,452 transactions for sale

Over the same period, the volumes traded represented:

  • 276,797 DBV Technologies shares and 4,348,055.64 euros at the purchase
  • 302,092 DBV Technologies shares and 4,845,027.06 euros for sale

About DBV Technologies 
DBV Technologies is developing Viaskin®, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV Technologies is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

DBV Investor Relations Contact
Sara Blum Sherman
Senior Director, Investor Relations & Strategy
+1 212-271-0740
[email protected]

DBV Media Contact
Joe Becker
VP, Global Corporate Communications
+1 646-650-3912
[email protected]

Attachment


a d v e r t i s e m e n t